Difficulty: Medium
Average Score: 92%
Practice
An important difference between leuprolide and the new drug ganirelix is that ganirelix
Correct answer
C
Rationale
The correct answer is C) Immediately reduces gonadotropin secretion. Ganirelix is a gonadotropin-releasing hormone (GnRH) antagonist that acts quickly to inhibit the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This rapid suppression of gonadotropin secretion is crucial in certain clinical situations, such as assisted reproductive technologies, where precise control of the timing of ovulation is needed.
Option A) Can be administered as an oral formulation is incorrect because ganirelix, like leuprolide, is administered via subcutaneous injection. This route is necessary for the drug to achieve the desired pharmacokinetic profile and therapeutic effect.
Option B) Can be used alone to restore fertility to hypogonadal men and women is incorrect because ganirelix alone is not sufficient to restore fertility in hypogonadal individuals. It is typically used in conjunction with other medications as part of a controlled ovarian hyperstimulation protocol for assisted reproduction.
Option D) Initially stimulates pituitary production of LH and FSH is incorrect because ganirelix, as a GnRH antagonist, works by blocking the GnRH receptors in the pituitary gland, thereby inhibiting the production and release of LH and FSH. There is no initial stimulation of gonadotropin production with ganirelix.
Understanding the mechanism of action of gonadotropin-releasing hormone agonists and antagonists is essential in the field of endocrine pharmacology, particularly in the management of infertility and hormonal disorders. By grasping the specific actions of these drugs, healthcare providers can make informed decisions regarding their use in clinical practice to optimize patient outcomes.
Option A) Can be administered as an oral formulation is incorrect because ganirelix, like leuprolide, is administered via subcutaneous injection. This route is necessary for the drug to achieve the desired pharmacokinetic profile and therapeutic effect.
Option B) Can be used alone to restore fertility to hypogonadal men and women is incorrect because ganirelix alone is not sufficient to restore fertility in hypogonadal individuals. It is typically used in conjunction with other medications as part of a controlled ovarian hyperstimulation protocol for assisted reproduction.
Option D) Initially stimulates pituitary production of LH and FSH is incorrect because ganirelix, as a GnRH antagonist, works by blocking the GnRH receptors in the pituitary gland, thereby inhibiting the production and release of LH and FSH. There is no initial stimulation of gonadotropin production with ganirelix.
Understanding the mechanism of action of gonadotropin-releasing hormone agonists and antagonists is essential in the field of endocrine pharmacology, particularly in the management of infertility and hormonal disorders. By grasping the specific actions of these drugs, healthcare providers can make informed decisions regarding their use in clinical practice to optimize patient outcomes.